For the estimated 2.7 million people in the United States who suffer from obsessive-compulsive disorder (OCD), prescription pharmacological therapy involves the use of several approved therapies (e.g., sertraline [Pfizer’s Zoloft, generics]), as well as off-label therapies from multiple drug classes. Even though the OCD drug market is highly genericized, the heterogenous nature of both the disorder and patients’ response to treatment provides opportunity for branded drugs (e.g., Trintellix [Lundbeck/Takeda]) to be introduced into the treatment paradigm, often as later-line therapies. Our Treatment Algorithms: Claims Data Analysis provides national patient-level claims data to explore the use of key therapies in both newly diagnosed and recentlytreated patients.

Questions Answered

  • What patient share do key therapies and brands garner by line of therapy in newly diagnosed OCD patients? What are the quarterly trends in prescribing among recentlytreated and newly diagnosed OCD patients?
  • How have branded antidepressants (e.g., Trintellix [Lundbeck/Takeda]) and atypical antipsychotics (e.g., Latuda [Sunovion], Vraylar [Allergan]) been integrated into the treatment algorithm?
  • What proportion of OCD patients receive drug therapy within two years of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within two years of diagnosis?
  • What percentage of OCD patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?
  • What are the product-level compliance and persistency rates among drug-treatedOCD patients?

Product Description

Treatment Algorithms: Claims Data Analysis provides detailed analysis of brand usage across different lines of therapy using real-world patient-level claims data so that clients can accurately assess their source of business and quantify areas of opportunity for increasing their brand share.

Markets covered: United States

Real-world data: Longitudinal patient-level claims data analysis

Key companies: Lundbeck, Takeda, Sunovion, Allergan

Key drugs: Bupropion (Wellbutrin, other brands, generics), clomipramine (Anafranil, generics), fluoxetine (Prozac, generics), sertraline (Zoloft, generics), venlafaxine (Effexor, generics)

Key analysis provided:

  • Brand use across longitudinal patient sample.
  • Newly diagnosed patient analysis.
  • Treatment initiation and progression.
  • Line of therapy analysis.
  • Combination therapy analysis.
  • Source of business for recently treated patients.
  • Persistency and compliance analysis.
  • Product-level patient flowcharts.

Table of contents

  • Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)
    • Treatment Algorithms - Claims Data Analysis - Obsessive Compulsive Disorder US Analysis [May 2018]

Author(s): Joyce Spadafora, ALM

Joyce is a business insights analyst in Decision Resources Group’s central nervous systems and ophthalmology division, where she provides expert insight into commercial aspects of drug development and market sizing across psychiatric and pain indications. She has worked extensively in DRG’s schizophrenia and chronic pain content. Prior to joining DRG, Joyce spent several years in the biotech industry focused in research and development and in biotech consulting. Her project experience covered indications including psychiatry, pain, infectious diseases, respiratory, and ophthalmology. Beyond my therapeutic and industry knowledge, she holds a Masters in Extension Studies in Psychology from Harvard University and a in Mechanical Engineering with Biology from the Massachusetts Institute of Technology.


Related Reports

Obsessive-Compulsive Disorder | Epidemiology | Europe Data

DRG Epidemiology's coverage of obsessive-compulsive disorder (OCD) comprises epidemiological e...

View Details

Obsessive-Compulsive Disorder | Epidemiology | Mature Markets Data

DRG Epidemiology's coverage of obsessive-compulsive disorder (OCD) comprises epidemiological estimates of key patient populations across the...

View Details